Fibrolamellar Hepatocellular Carcinoma: An Immunohistochemical Comparison With Conventional Hepatocellular Carcinoma

被引:32
|
作者
Abdul-Al, Hala M. [1 ,2 ]
Wang, Guanghua [1 ]
Makhlouf, Hala R. [1 ]
Goodman, Zachary D. [1 ]
机构
[1] Armed Forces Inst Pathol, Washington, DC 20306 USA
[2] Ain Shams Univ, Sch Med, Cairo, Egypt
关键词
glypican-3; survivin; CK7; hepatocellular carcinoma; fibrolannellar carcinoma; immunohistochemistry; GLYPICAN-3; EXPRESSION; DYSPLASTIC NODULES; ONCOFETAL PROTEIN; DIAGNOSTIC-VALUE; MARKER; SURVIVIN; CANCER; PROLIFERATION; VESSELS; MATRIX;
D O I
10.1177/1066896910364229
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The fibrolamellar variant of hepatocellular carcinoma (FLC) differs from conventional hepatocellular carcinoma (HCC) in some clinical and pathological features. The authors investigated possible differences in reactivity between FLCs and HCCs using glypican-3 (GPC3), an oncofetal protein, and survivin, an antiapoptotic protein. They also compared staining of FLC and HCC with antibodies to cytokeratins 7 (CK7) and 19 (CK19) and CD34. GPC3 was significantly more often and more strongly expressed in HCCs (72%) than in FLCs (17%). Survivin nuclear translocation in tumor cells did not differ between HCCs (10%) and FLCs (9%). There was more abundant expression of CK7 in FLCs (92%) than in HCCs (33%), whereas CK19 was more often found in HCCs (20%) than in FLCs (5%). All tumors had CD34-positive sinusoids. This study shows that FLCs and HCCs differ in the expression of GPC3, CK7, and CK19 and that there is a lack of difference as regards survivin and CD34.
引用
收藏
页码:313 / 318
页数:6
相关论文
共 50 条
  • [1] Stemness Characteristics of Fibrolamellar Hepatocellular Carcinoma: Immunohistochemical Analysis with Comparisons to Conventional Hepatocellular Carcinoma
    Zenali, Maryam J.
    Tan, Dongfeng
    Li, Wei
    Dhingra, Sadhna
    Brown, Robert E.
    [J]. ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2010, 40 (02): : 126 - 134
  • [2] Immunohistochemical detection of procalcitonin in fibrolamellar hepatocellular carcinoma
    Kotaro Matsumoto
    Kentaro Kikuchi
    Ayako Hara
    Hiromichi Tsunashima
    Koichi Tsuneyama
    Shinpei Doi
    [J]. Clinical Journal of Gastroenterology, 2021, 14 : 827 - 830
  • [3] Immunohistochemical detection of procalcitonin in fibrolamellar hepatocellular carcinoma
    Matsumoto, Kotaro
    Kikuchi, Kentaro
    Hara, Ayako
    Tsunashima, Hiromichi
    Tsuneyama, Koichi
    Doi, Shinpei
    [J]. CLINICAL JOURNAL OF GASTROENTEROLOGY, 2021, 14 (03) : 827 - 830
  • [4] Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis
    Kakar, S
    Burgart, LJ
    Batts, KP
    Garcia, J
    Jain, D
    Ferrell, LD
    [J]. MODERN PATHOLOGY, 2005, 18 (11) : 1417 - 1423
  • [5] Fibrolamellar Hepatocellular Carcinoma
    Shahi, Niharika
    Chung, Andrew David
    [J]. APPLIED RADIOLOGY, 2023, 52 (02) : 48A - 48C
  • [6] Fibrolamellar Hepatocellular Carcinoma
    Liu, Shu
    Chan, Kwok Wah
    Wang, Bingyuan
    Qiao, Liang
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (10): : 2617 - 2624
  • [7] Fibrolamellar hepatocellular carcinoma
    Smith, Mitchell T.
    Blatt, Ellen R.
    Jedlicka, Paul
    Strain, John D.
    Fenton, Laura Z.
    [J]. RADIOGRAPHICS, 2008, 28 (02) : 609 - 613
  • [8] Fibrolamellar hepatocellular carcinoma
    Koudah, Sabrina
    El Mouhadi, Sanaa
    Arrive, Lionel
    [J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2012, 36 (01) : 5 - 6
  • [9] Managing fibrolamellar hepatocellular carcinoma
    Grandhi, Miral Sadaria
    Pawlik, Timothy M.
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (02): : 143 - 152
  • [10] FIBROLAMELLAR HEPATOCELLULAR-CARCINOMA
    FRIEDMAN, AC
    LICHTENSTEIN, JE
    GOODMAN, Z
    FISHMAN, EK
    SIEGELMAN, SS
    DACHMAN, AH
    [J]. RADIOLOGY, 1985, 157 (03) : 583 - 587